Wilfried Hornberger

USPTO Granted Patents = 85 (Patent Applications = 20)

CIPO Patents = 11 (Patent Applications = 24)

EPO Patents = 24 (Patent Applications = 37)

Average Co-Inventor Count = 6.7

ph-index = 11

Forward Citations = 397(Granted Patents)

Forward Citations (Not Self Cited) = 299(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Neustadt, DE (1998 - 2017)
Wiesbaden, DE (2014 - 2017)
Ludwigshafen, DE (1995 - 2020)

Company Filing History:

43 out of 167

Abbvie Deutschland Gmbh and Co Kg

Abbott Laboratories Corporation

patents

5. 7 out of 10,754

Basf Aktiengesellschaft

7. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2020

Loading Chart...

Areas of Expertise:

Fused Heterocyclic Compounds

Glycogen Synthase Kinase-3 Inhibitors

Oxindole Derivatives

Vasopressin-Related Diseases

Carboxamide Compounds

Calpain Inhibitors

Phenalkylamine Derivatives

Tetrahydroisoquinolines

Amidomethyl-Substituted Oxindole

Substituted Oxindole Derivatives

Heteroaryl-Substituted Derivatives

Benzazepine Derivatives

85 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10556907 - Fused heterocyclic compounds as S1P modulators (2020-02-11),

2. 10100048 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors (2018-10-16),

3. 9862704 - Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases (2018-01-09),

4. 9840495 - Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases (2017-12-12),

5. 9688678 - Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases (2017-06-27),

6. 9657002 - Oxindole derivatives carrying an oxetane substituent and use thereof for treating vassopressin-related diseases (2017-05-23),

7. 9617226 - Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases (2017-04-11),

8. 9567325 - Carboxamide compounds and their use as calpain inhibitors (2017-02-14),

9. 9540370 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors (2017-01-10),

10. 9527856 - Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases (2016-12-27),

11. 9527811 - Carboxamide compounds and their use as calpain inhibitors (2016-12-27),

12. 9487505 - Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them (2016-11-08),

13. 9434713 - 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases (2016-09-06),

14. 9422264 - Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases (2016-08-23),

15. 9403796 - Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses (2016-08-02),

Wilfried Hornberger: Innovator Extraordinaire

Introduction:

In the world of patents and innovations, some individuals stand out for their exceptional contributions in advancing scientific and technological frontiers. One such prominent figure is Wilfried Hornberger, hailing from Ludwigshafen, Germany. With an impressive record of 85 patents to his name, Hornberger's groundbreaking work has significantly impacted various fields. In this article, we will delve into his latest patents, career highlights, notable collaborations, and the lasting legacy he has carved out.

Latest Patents:

Wilfried Hornberger's recent patents highlight his proficiency in developing compounds for medical treatments. One of his notable inventions includes "Fused Heterocyclic Compounds as S1P Modulators." This creation focuses on novel heterocyclic compounds that act as S1P modulators, exhibiting potential therapeutic applications for diseases or disorders mediated by an S1P receptor. Additionally, he has pioneered the development of another set of compounds titled "Heterocyclic Compounds and Their Use as Glycogen Synthase Kinase-3 Inhibitors." These compounds showcase their efficacy in inhibiting glycogen synthase kinase 3 (GSK-3), opening new avenues for treatment possibilities.

Career Highlights:

Throughout his illustrious career, Wilfried Hornberger has made significant contributions to the scientific community. He has worked with esteemed organizations such as AbbVie Deutschland GmbH and Co KG, as well as Abbott GmbH & Co KG. Hornberger's groundbreaking research and innovative expertise have propelled him to be a leading figure in the field. His 85 patents undoubtedly attest to his profound knowledge and dedication to pushing boundaries.

Collaborations:

In his journey towards innovation, Wilfried Hornberger has collaborated with remarkable professionals who have complemented his expertise. Notable among them are his coworkers Helmut Mack and Wilfried Lubisch. The synergy between these individuals has undoubtedly contributed to the successful realization of their inventions. Such collaborations exemplify the power of teamwork and collaboration in driving breakthrough innovations.

Conclusion:

Wilfried Hornberger's genius and dedication to his craft have solidified his place as an outstanding innovator. His array of patents, including the groundbreaking "Fused Heterocyclic Compounds as S1P Modulators" and "Heterocyclic Compounds and Their Use as Glycogen Synthase Kinase-3 Inhibitors," demonstrate his ability to make a lasting impact in the medical field. As an AI assistant at idiyas.com, we celebrate and acknowledge his remarkable contributions, forever leaving a mark in the realm of innovations and patents.

This text is generated by artificial intelligence and may not be accurate.